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Genome-scale deﬁnition of the transcriptional programme
associated with compromised PU.1 activity in acute myeloid
leukaemia
JI Sive, S Basilico, R Hannah, SJ Kinston, FJ Calero-Nieto and B Göttgens
Transcriptional dysregulation is associated with haematological malignancy. Although mutations of the key haematopoietic
transcription factor PU.1 are rare in human acute myeloid leukaemia (AML), they are common in murine models of radiation-
induced AML, and PU.1 downregulation and/or dysfunction has been described in human AML patients carrying the fusion
oncogenes RUNX1-ETO and PML-RARA. To study the transcriptional programmes associated with compromised PU.1 activity, we
adapted a Pu.1-mutated murine AML cell line with an inducible wild-type PU.1. PU.1 induction caused transition from leukaemia
phenotype to monocytic differentiation. Global binding maps for PU.1, CEBPA and the histone mark H3K27Ac with and without
PU.1 induction showed that mutant PU.1 retains DNA-binding ability, but the induction of wild-type protein dramatically increases
both the number and the height of PU.1-binding peaks. Correlating chromatin immunoprecipitation (ChIP) Seq with gene
expression data, we found that PU.1 recruitment coupled with increased histone acetylation induces gene expression and activates
a monocyte/macrophage transcriptional programme. PU.1 induction also caused the reorganisation of a subgroup of CEBPA
binding peaks. Finally, we show that the PU.1 target gene set deﬁned in our model allows the stratiﬁcation of primary human AML
samples, shedding light on both known and novel AML subtypes that may be driven by PU.1 dysfunction.
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INTRODUCTION
Production of mature haematopoietic cells is regulated by a
complex network of transcription factors (TFs), which together
with epigenetic regulators drive cellular decision-making pro-
cesses in response to external cues. Disturbance of these networks
can lead to malignant transformation, for example, RUNX1 and
its binding partner CBFB control multiple aspects of normal
haematopoiesis, but fusion proteins such as RUNX1-ETO or CBFB-
MYH11 can cause acute myeloid leukaemia (AML).1,2
PU.1 is an ETS-family TF that has multiple roles in normal
haematopoiesis. Structurally, it consists of a transactivating region,
a middle PEST region involved in protein–protein interactions
particularly with the IRF TFs and a C-terminal DNA-binding
domain.3 PU.1 was recently shown to contribute to the early
establishment of haematopoietic transcriptional programmes,4
and is known to have a key role during foetal haematopoiesis.5,6
In the adult, PU.1 functions as a major determinant of both
myeloid and B-cell lineages7,8 with its effect often modulated by
interactions with other TFs such as CEBPA,9 GATA110 and c-JUN.11
More recently, PU.1 has been identiﬁed as a major regulator of cell
cycle both in blood stem cells and during myeloid maturation.12,13
Loss of PU.1 in murine models can cause AML, but the precise
relationship and mechanism remains unclear. Germ-line knock-
outs of Pu.1 cause lethality either in utero5 or soon after birth,6,14
whereas partial knockdown to levels of 20% by deletion of the
Pu.1-14 Upstream Regulatory Element is compatible with foetal
life, but causes AML within 3–8 months. This had led to the theory
that residual PU.1 activity is required to promote leukaemogenesis.15
However, an alternative model with somatic Pu.1 deletion causing
a complete loss of protein also causes AML,16 and Pu.1 hypo-
morphic mutants are frequently observed in radiation-induced
mouse models of AML.17–20 This suggests that any loss of PU.1
below a certain threshold may be sufﬁcient for leukaemogenesis;21
however, a recent report suggests that some PU.1 function/levels
are needed to maintain stem cell function of leukaemic cells.22
Although cases of PU.1 and Upstream Regulatory Element
mutations have been recorded in human AML, they are much
rarer than in mice.23–27 Better described are mechanisms
suppressing PU.1 function, such as disruption of PU.1 transactiva-
tion activity by RUNX1-ETO,11 or interference with PU.1 binding
(including at its own promoter site) by PML-RARA.28 Importantly,
there has as yet been no speciﬁc investigation into the
transcriptional programmes associated with the loss of PU.1
activity in AML.
To investigate the effects of restoring wild-type PU.1 to a PU.1
mutant leukaemia model, we developed an inducible PU.1 system,
and showed that the induction of wild-type protein causes transit
from the leukaemic state to monocytic differentiation. Using
chromatin immunoprecipitation (ChIP)-Seq, we produced
genome-scale maps of DNA binding by PU.1, the associated TF
CEBPA and the H3K27Ac histone mark before and after PU.1
induction, and complemented these with gene expression
proﬁling data. Unexpectedly, mutant PU.1 was bound to a large
number of genomic regions, but induction of wild-type PU.1
resulted in a substantial expansion of binding sites, a subset of
which was associated with elevated histone H3K27 acetylation,
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which in turn correlated with increased expression of nearby
target genes. Our results also show that de novo binding of wild-
type PU.1 has the capacity to recruit CEBPA to a subset of new
sites. Finally, we show that the PU.1 target gene set in our model
can be utilised to stratify primary human AML samples, shedding
light on both known and novel AML subtypes that may be driven
by PU.1 dysfunction.
MATERIALS AND METHODS
Cell culture
X18.1.1 cells were maintained in high glucose RPMI 1640 supplemented
with 10% foetal calf serum, 1% penicillin/streptomycin, 300 μM asparagine,
2 mM L-glutamine and 50μM beta-mercaptoethanol. Cells were partially
adherent requiring trypsin treatment for passage, and were maintained at
3–10 × 105 cells/ml.
DNA and RNA
Genomic DNA was puriﬁed by phenol-chloroform extraction. RNA was
extracted using Tri-Reagent (Sigma, Dorset, UK) and then treated with
DNase I (Ambion, Paisley, UK), following the manufacturer’s speciﬁcations.
For DNA sequencing, exonic fragments of endogenous Pu.1 were ampliﬁed
by PCR and cloned into the PGEM-T Easy vector (Promega, Southampton,
UK). Both strands of all ﬁve exons were sequenced and compared with the
Pu.1 sequence of reference (obtained from Ensembl). Integration of PuER
was conﬁrmed by PCR using primers encompassing the Pu.1-ERTM fusion
region. All primers used are listed in Supplementary Table 1.
Viral transduction
X18.1.1 cells were transduced with PuER or empty vector (EV) control
using retrovirus produced with Psi-Eco Retrovirus packaging vector
(Clontech, Saint-Germain-en-Laye, France) in 293 T cells. Cells were
infected by centrifugation in the presence of polybrene and then selected
with 0.5 μg/ml puromycin. Clonal cell lines were obtained by limiting
dilution and further expanded. 4-Hydroxytamoxifen (OHT) (Sigma) induc-
tions were carried out at 100 nM.
Fluorescence-activated cell sorting and cell proliferation assays
Flow cytometry was performed on a BD LSRFortessa (Oxford, UK) cell
analyser using the following antibodies: CD11b (BioLegend, London, UK;
101212) and F4/80 (BioLegend, 123113). Cell proliferation was assayed by
counting live cells following Trypan Blue exclusion.
Immunoblotting
Protein lysate in modiﬁed RIPA buffer (50mM TriS pH7.4, 150mM NaCl, 1%
NP40, 0.25% Na deoxycholate, 1 mM EDTA) was run on a 12% sodium
dodecyl suphate polyacrylamide gel, and transferred to polyvinylidene
ﬂuoride membrane by overnight wet blotting. Membranes were probed
using primary antibodies against ERα (Santa Cruz Biotechnologies,
Heidelberg, Germany; sc542x), PU.1 (Santa Cruz Biotechnologies, sc352x)
and β-actin (Sigma, A5441).
ChIP sequencing
ChIP was performed as previously described29 using the following
antibodies: PU.1 (Santa Cruz Biotechnologies, sc352x), CEBPA (Santa Cruz
Biotechnologies, sc61x), H3AcK27 (Abcam, Cambridge, UK; ab4729) and
rabbit IgG (Sigma, I5006). Library construction was performed using the
Illumina TruSeq DNA Sample Kit (Illumina, Cambridge, UK) according to the
manufacturer's instructions. Sequencing was performed on the Illumina
HiSeq 2000 platform. Reads were mapped to the mm10 mouse reference
genome using Bowtie2.30 Mapped reads were converted to density plots
and displayed as UCSC genome browser custom tracks, and peaks called
using MACS2.31
Using BEDTools,32 ChIP‐Seq peak coordinates were combined between
PU.1− and PU.1+ conditions for each TF ChIP, and peaks overlapping by at
least 1 bp were merged. Coverage scores were counted using the
intersectBed function for each merged peak region, and then normalised
for peak length and total read counts (per 1 million reads). For H3K27Ac,
read coverage regions were extended to 800 bp, and then normalised
as above.
Microarray gene expression analysis
Triplicate samples were ampliﬁed using TotalPrep 96‐RNA ampliﬁcation kit
(Applied Biosystems, Paisley, UK/Ambion) and hybridised to MouseWG‐6v2
microarrays (Illumina) by Cambridge Genomic Services. Raw data were
ﬁltered in R to remove any probes with detection call ⩾ 0.01 in all samples,
and then transformed by variance-stabilising transformation in the lumi
package.33 Data were quantile‐normalised, and differentially expressed
probes identiﬁed using the limma package.34 Probes with adjusted
P‐value⩽ 0.05, and fold change41.2 were considered signiﬁcant.
Data analysis
Normalised ChIP-Seq read counts were combined into one matrix and
used for subsequent differential score calculations and correlation
analyses, as well as integration of ChIP-Seq and gene expression data.
All analysis was performed in R with plots created using ggplot2.35
Peaks were assigned to genes using annotation from UCSC. Peaks
within regions contained in the mammalian promoter database
MPromdDb were allocated to promoter or within the gene body to
intragenic. The remaining intergenic peaks were assigned to both the
nearest 5’ and 3’ genes. If no gene was found within 50 kb of an intergenic
peak, it was not assigned to any gene. De novo motif analysis on the
central 80 bp peak regions was performed using Homer.36 Only signiﬁcant
motifs (q‐value⩽ 0.01) with ⩾ 5% peak coverage were reported. Geneset
enrichment analyses were performed using Enrichr.37 ChIP-Seq peaks were
compared with those of primary macrophages (GSM537983)36 using the
Codex webtool.38 PU.1 target genes were used for unsupervised analysis of
published expression arrays (GSE34723 (ref. 39) and GSE6891 (ref. 40)) in R
with the pvclust package.41 Heatmaps were generated using the heatmap.2
function from the gplots package.42
GEO data deposition
The raw and processed data from the ChIP‐Seq and microarray
experiments reported in this publication have been submitted to the
NCBI Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo) and assigned
the identiﬁer GSE63317.
RESULTS
Establishment and validation of an inducible rescue model of
leukaemia dependent on loss of functional PU.1
To investigate the role of reduced PU.1 in AML, we utilised a
radiation-induced murine AML cell line X18.1.1,18 characterised by
hemizygous deletion of one Pu.1 allele, and two missense
mutations in the remaining allele: an R235C substitution within
the DNA-binding domain and a 30 amino acid deletion affecting
the PEST domain (Figure 1a). We conﬁrmed these mutations by
resequencing both genomic and cDNA.
Enforced expression of wild-type PU.1 in X18.1.1 cells has
previously been shown to inhibit clonogenic growth, induce
monocytic differentiation and elicit apoptosis.18 To study the
mechanisms underlying this PU.1-induced exit from a leukaemic
transcriptional programme, we virally transduced cells with either
an OHT-inducible Pu.1-ERTM fusion gene (PuER)43 or a control EV
within an MSCV-puro retroviral packaging system (Figure 1a).
Incubation in 100 nM OHT caused marked cessation of cell
proliferation in liquid culture, reduction of CD117 expression and
increased expression of the cell surface markers CD11b and F4/80,
consistent with maturation towards a monocytic phenotype
(Supplementary Figures 1a and b). We then obtained clonal
populations produced by limiting dilution and individual clones
with minimal ‘leakage’ (PU.1 activity without OHT induction) were
selected for further investigation. Clonal populations showed the
same characteristics (Figures 1b and c and Supplementary Figure 1c).
The stable integration of PuER was conﬁrmed in PuER lines by
PCR, PU.1 mRNA levels quantiﬁed by qPCR in PuER lines
(Supplementary Figure 2) and PuER protein identiﬁed by
immunoblotting with anti-ERα antibody (Figure 1d). Anti-PU.1
antibody conﬁrmed the identity of the detected band, and
interestingly also detected substantial signal at the size expected
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for endogenous PU.1 in both control and PuER-transduced cells.
This demonstrates that the Pu.1 mutations do not prevent protein
translation, and suggests that the phenotype is the result of
functional deﬁciencies in genomic PU.1 binding.
Induction of wild-type PU.1 causes qualitative and quantitative
changes to PU.1 binding
We next utilised this model to investigate the immediate changes
in transcriptional control that accompany Pu.1-driven exit out of
leukaemic proliferation. PU.1 primarily acts as a transcriptional
activator, and can function in concert with CEBPA.44,45 We
therefore generated genome-wide ChIP-Seq data for the TFs
PU.1 and CEBPA, and the H3K27Ac histone mark associated with
transcriptional gene activation, at time 0 and 2 h after incubation
in 100 nM OHT, in clonal samples for EV and PuER (henceforth
designated PU.1− and PU.1+, respectively). Finally, RNA for gene
expression microarrays was prepared from the same experiment,
to link alterations in TF occupancy and/or histone modiﬁcation
levels with transcriptional changes (Figure 2a).
ChIP-qPCR assessment at the -14 Upstream Regulatory Element
Pu.1-binding site revealed PU.1 binding in both EV and PuER
clones, but with almost doubling of the enrichment in the PuER
clone following OHT induction (Supplementary Figure 3a). This
indicates that despite mutation of the DNA-binding domain,
mutant PU.1 protein still possesses DNA-binding ability, although
its functionality is likely to be impaired because we now show that
it is unable to transactivate known PU.1 target gene promoters
(Supplementary Figures 3b and c).
ChIP-Seq analysis with and without PU.1 induction revealed
examples of both new PU.1-binding events, and increased binding
at previously bound peaks (Figure 2b and Supplementary Figure
3d), with a total of 5283 PU.1 peaks in the absence of wild-type
PU.1, increasing to 15 675 following induction, including 12 695
not previously detected (Figure 2c). Quantitative assessment of
read counts per region, revealed a mean 7.5-fold increase in
coverage score (Figure 2d) across all regions, indicating a
generalised increase in PU.1 binding. Finally, comparing the peak
regions bound by mutant and/or wild-type PU.1 with previously
published data for PU.1 binding in primary macrophages,36
showed a signiﬁcant overlap of binding peaks especially for
wild-type PU.1 (Figure 2e).
This analysis demonstrates that although mutant PU.1 protein
remains able to bind DNA, there is an increase in both the number
and height of the peaks following wild-type PU.1 induction, with
this binding proﬁle showing substantial similarity to that in
macrophages. As induction of wild-type PU.1 can overcome the
Figure 1. Production and validation of PuER-inducible cell lines. (a) Parental cell line X18.1.1 contains a hemizygous deletion of one Pu.1 allele.
The remaining allele carries an R235C substitution in the DNA-binding domain and a deletion (137–166) involving the PEST domain. X18.1.1
cell line was retrovirally transduced with MSCV-puro-PuER or control MSCV-puro EV. After puromycin selection, clonal lines were obtained by
limiting dilution. (b) Cell growth was speciﬁcally arrested in PuER line after 4 days of OHT incubation. Cell growth was monitored for two
selected clonal lines, EV (E1) and PuER (P2), during 4 days in presence (+ OHT) or absence (−OHT) of OHT. Mean and standard error of the
mean (s.e.m.) for two different experiments (each one performed in triplicate) are shown. (c) Restoration of wild-type PU.1 induces the
upregulation of CD11b and F4/80 surface markers. Fluorescence-activated cell sorting results corresponding to CD11b and F4/80 surface
expression in EV (E1) and PuER (P2) clonal lines after 4 days in presence (+ OHT) or absence (−OHT) of OHT are shown. (d) PuER protein
detection by western blot. Mutant (endogenous) PU.1 protein can be detected in all samples (parental X18.1.1 line, EV and PuER bulk
populations and selected clonal lines E1, E2, P1 and P2) using an antibody against PU.1. PUER fusion protein could only be detected in PuER
bulk populations and selected clonal lines P1 and P2 when using antibodies against ERα and PU.1. Detection of β-actin was used a control.
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differentiation block of X18.1.1 cells, the changes in PU.1 binding
are presumably responsible for the initiation of a transcriptional
programme that can exit from the leukaemic state into normal
monocytic differentiation.
Induction of wild-type PU.1 increases histone acetylation
predominantly at enhancers
Comparison across all PU.1-bound regions revealed a positive
correlation between changes in PU.1 binding and those of
H3K27Ac (Pearson correlation 0.37, Po0.0001) (Supplementary
Figure 4a), indicating that the induction of wild-type PU.1 leads to
co-localisation of histone modiﬁcations associated with increased
transcriptional activity at many of its target sites (Figure 3a). On
the basis of these results, we deﬁned a set of peaks representing
functional PU.1 binding (Group I, n= 1734) deﬁned by (i) ⩾ four-
fold increase in PU.1 read count, (ii) ⩾ fourfold increase in
H3K27Ac read count and (iii) H3K27Ac read number ⩾ 50 per
region. For comparison, we looked at peaks with ⩾ fourfold
increase in PU.1 but unchanged H3K27Ac (Group II, n= 5056), and
those with no change in PU.1 (Group III, n= 2761) (Figure 3b). Of
note, de novo motif discovery demonstrated that ETS motifs
previously reported to be bound speciﬁcally by Pu.1 were more
highly enriched in Group I than Group II peaks (Supplementary
Figure 5).
Analysis of the genomic distribution of PU.1-binding peaks
revealed a marked enrichment of the peaks with increased read
counts for intra- and intergenic localisation (95.0% and 91.5% for
Groups I and II, respectively) compared with those with no read-
count change (65.9 for Group III). Even though the association of
peaks to genes is complicated by the increased recognition of
long range promoter-enhancer interactions,46 our data are
consistent with tissue-speciﬁc functions of PU.1 being largely
mediated by enhancer region binding,36 and shows that these
binding events may have an important role in the phenotypic
switch to monocytic maturation.
PU.1 recruitment coupled with increased histone acetylation
induces gene expression and activates a monocyte/macrophage
transcriptional programme
We next explored the early transcriptional consequences of the
set of genomic regions associated with increased PU.1 binding
and H3K27 acetylation. Unsupervised hierarchical clustering of
gene expression proﬁles after only 2 h of induction, separated the
samples into two groups corresponding to the presence or
absence of wild-type PU.1 (Supplementary Figure 4b). We
associated the PU.1 peak sets to genes, and compared expression
proﬁles before and after OHT induction. We calculated the fold-
change for those genes with a false discovery rate-adjusted
P-value of o0.05 and compared the overall change of expression
for each of the three groups previously deﬁned. Not only were
many of the genes that changed expression associated with
Group I peaks (96 out of 284), but also genes associated to Group I
showed the most increased expression following PU.1 induction,
compared with Group II and Group III peaks (fold-change 1.76 vs
Figure 2. PU.1 ChIP-Seq binding proﬁles following wild-type PU.1 induction. (a) Experimental design. Samples for ChIP-Seq (using antibodies
against PU.1, CEBPA and H3K27Ac) and gene expression microarray analysis were collected after 2 h incubation in the presence of OHT for two
selected clonal lines, E1 (EV) and P2 (PuER). Samples for E1 and P2 were designated PU.1− and PU.1+, respectively. (b) New and stronger PU.1-
bound regions can be detected after induction of wild-type PU.1. The genome browser screenshots show a comparison of PU.1-binding
proﬁles between PU.1− and PU.1+ on the Cd14 (upper) and Elf1 (bottom) gene loci. A new peak at Cd14 locus and a higher peak at Elf1 locus
can be detected following wild-type Pu.1 induction. (c) Global PU.1-binding site comparison between PU.1− and PU.1+ conditions. (d) Read
count comparison between PU.1− and PU.1+ conditions, plotted as log2 of normalised read counts (per million reads) at PU.1 peaks, is shown.
Line corresponding to direct correlation (no change) is depicted. (e) Global PU.1-binding site comparison between PU.1− and PU.1+
conditions and a published macrophage dataset (GSM537983). Strong overlapping between PU.1+ and macrophage datasets can be
observed.
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0.82, Po0.0001 and 1.76 vs 0.81, Po0.0001, respectively)
(Figure 4a). This conﬁrms that even at the early time-point of
2 h, recruitment of wild-type PU.1 accompanied by increased
H3K27 acetylation initiates a PU.1-driven transcriptional
programme.
To further examine the relationship between PU.1-binding
events and gene expression, we took the 96 gene overlap of the
1282 genes mapped from the PU.1 Group I peaks with the 284
genes that showed increased expression following PU.1 induction
(Figure 4b). Gene ontology analysis of this 96 PU.1 target gene list
revealed overrepresented biological functions to be apoptosis and
humoral immune response, while enrichment analysis showed
strongest overlaps with expression proﬁles speciﬁc to macro-
phages or dendritic cells (Supplementary Table 2).
Finally, we used the PU.1 target genes to perform unsupervised
hierarchical clustering of gene expression proﬁles for 39 murine
haematopoietic cell types39 (Figure 4c, Supplementary Figure 6).
This produced six major clusters, of which Cluster 6 was
characterised by the highest expression levels of Pu.1, and
consisted exclusively of myeloid and monocytic cells. Intermediate
clusters showed a B-cell bias in those with higher Pu.1 expression,
whereas Cluster 1 consisting exclusively of T-cell subtypes had the
lowest Pu.1 expression levels (Figure 4d). This is consistent with
the known functions of PU.1 in myeloid and B-cell differentiation,
and validates our gene list as representing physiological PU.1-
driven pathways.
Restoring functional PU.1 causes reorganisation of CEBPA binding
On investigating the relationship between PU.1 and CEBPA
(Figure 5a), ChIP-Seq data showed that the overall peak numbers
were much higher for CEBPA with 26 098 peaks present before
and 20 569 peaks present after wild-type PU.1 induction
(Figure 5b), with mean read count over all regions essentially
unchanged. However, 2465 regions were called as peaks only after
PU.1 induction, and these showed a mean 2.3-fold increase in read
count, suggesting a discrete group of CEBPA-binding events
enhanced by the presence of active PU.1 (Figure 5c).
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To deﬁne relevant CEBPA peaks, we used the same methodology
as above and deﬁned a set of 405 Group I peaks deﬁned by
increased CEBPA and increased H3K27Ac read count (Figure 5d).
Again, control groups representing CEBPA increase without
H3K27Ac change (Group II, n= 21) and unchanged CEBPA binding
(Group III, n= 25 107) were selected for comparison. The small
number of Group II peaks indicates that the vast majority of CEBPA
peaks with increased binding after PU.1 induction were associated
with H3K27Ac change, and are likely to be functionally relevant for
gene transcription (Figure 5d).
As with PU.1, the Group I CEBPA peaks were relatively enriched
at intra- and intergenic regions (95.3%), when compared with
Group II and Group III (90.4% and 86.5% respectively) (Figure 5d).
Comparing the effect on expression from the genes mapped from
these peak sets, again revealed that Group I genes showed
signiﬁcantly higher expression after PU.1 induction (2.1-fold)
compared with those from Group III which showed no fold-
change. There were no genes mapped from the small number of
Group II CEBPA peaks that corresponded to genes with altered
expression on the array (Supplementary Figure 4c). These results
show that although there is widespread CEBPA binding before
PU.1 induction, a small subset of binding regions are induced by
wild-type PU.1 binding, and may contribute to the transcriptional
programme.
De novo motif analysis of the PU.1 peak sequences showed
CEBPA motifs overrepresented in all three groups of PU.1 peaks
deﬁned in the previous section. However, the percentage of
regions with CEBPA motifs was higher in Group I PU.1 peaks
(36.0%), compared with either Group II (26.4%) or Group III (26.1%)
(Supplementary Table 3). This observation suggested that either
(i) Group I PU.1 peaks preferentially bind to regions already
‘bookmarked’ by prior CEBPA binding or, alternatively, (ii) Group I
PU.1 peaks bind to new genomic regions, and themselves act as
markers for new CEBPA binding.
Group I Group II Group III
lo
g2
 F
C 
Ge
ne
 E
xp
re
ss
io
n 
1734 
PU.1 Group I Peaks
1282 
PU.1 Group I Genes
284
Overexpressed Genes
96
PU.1 Target Genes
1.0
-1.0
-0.5
0
0.5
G
ra
C
D
8pos_C
D
69pos
C
D
8pos_C
D
69neg
C
D
4pos_C
D
69neg
C
D
4pos_C
D
69pos
D
P
_C
D
69pos
D
P
_C
D
69neg
D
N
4
D
N
3b
D
N
3a
sC
M
P
M
P
P
b
G
M
LPa
G
M
LP
b
pG
MPa
pG
M
P
b
D
N
1
D
N
2
H
S
C
M
PPa
pM
E
P
M
kP
pC
FU
-E
M
E
P
FrC
FrB
FrD
FrE
T1B
T2B
M
zB
FoB
m
N
K
iN
K
preproB
B
LP
C
LP
G
M
P
M
ono
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Cluster 6
1 2 3 4 5 6
6
7
8
9
10
11
12
P
u.
1 
E
xp
re
ss
io
n
Cluster
Figure 4. Increased PU.1 binding and increased H3K27Ac enrichment deﬁne a set of target genes that can be used as classiﬁer for normal
haematopoietic cells. (a) Greatest upregulation can be detected in genes with increased PU.1 binding and increased H3K27Ac enrichment.
Plot shows overall changes in expression (log2FC) of genes from Groups I, II and III with a signiﬁcant variation of expression following wild-
type PU.1 induction. (b) Peaks in Group I (1734 regions) were associated to genes (1282 Group I genes) and intersected with genes that
showed increased expression on microarray analysis following 2-h PU.1 induction (284 genes) to obtain high conﬁdence PU.1 target genes (96
genes). (c) Unsupervised hierarchical clustering of gene expression from phenotypically deﬁned murine haematopoietic cell types39 on basis
of 89 of 96 PU.1 target genes expression present in dataset. Deﬁned clusters are indicated. Out of six deﬁned clusters, cluster 6 (integrated by
GMPs, granulocytes and monocytes) present highest levels of Pu.1 (d). (Full phenotypic deﬁnitions of cell types may be found in Seita et al.39)
PU.1 dysregulation in acute myeloid leukaemia
JI Sive et al
19
© 2016 Macmillan Publishers Limited Leukemia (2016) 14 – 23
Co-binding between peak sets showed that 355/1734 (20.5%) of
the Group I PU.1 peaks were at sites of pre-existing CEBPA, a
proportion no higher than that of the (presumably non-functional)
Group II and III PU.1 peaks (1331/5056 (26.33%) and 1517/2761
(54.94%), respectively). This does not support a signiﬁcant role for
CEBPA in marking sites for subsequent functional PU.1 binding.
We then investigated the alternative possibility that Group I PU.1
peaks bind to new genomic regions and recruit subsequent CEBPA
binding. Of the 405 Group I CEBPA peaks identiﬁed, 355 (87.7%)
were bound at Group I PU.1 peaks; in comparison, none (0.0%) of
them were co-bound by PU.1 Group III peaks (Figures 5e and f). This
suggests a role for wild-type PU.1 in making new regions available
for subsequent functional binding of CEBPA, but not the converse.
PU.1 target genes can predict human AML subtypes regulated by
PU.1 dysfunction
To assess the extent to which this murine model corresponds with
human AML, we used the PU.1 target gene set to perform
unsupervised hierarchical clustering of a set of 461 primary
human AML samples with genome-wide expression data40
(Figure 6a, Supplementary Figure 7). This generated three
clusters, of which Cluster 3 showed reduced levels of PU.1
expression, and contained 21/23 (91.3%) of the t(15;17)
translocations and 20/35 (57.1%) of the t(8;21) translocations
(Figures 6b and c). This may represent AML samples driven in
part by PU.1 underexpression and/or dysfunction. Cluster 1
samples had the highest levels of PU.1 expression, and were
predominantly M4/M5 FAB classiﬁcation (myelomonocytic/
monoblastic), suggesting a separate class of cases where high
PU.1 levels direct a degree of monocytic differentiation, but
alternative mechanisms are responsible for the leukaemia
phenotype (Figure 6c). Taken together, this analysis suggests
that the murine model is not only relevant for deﬁning PU.1
target genes that may be involved in the leukaemic phenotype
of t(15;17) and t(8;21) AML, but also that it may be exploited to
identify novel human AML subtypes.
Figure 5. Regions with increased CEBPA binding and increased H3K27Ac enrichment co-localise with regions with increased PU.1 binding and
increased H3K27Ac enrichment following wild-type PU.1 induction. (a) Genome browser screenshots show new regions bound by CEBPA
(middle two tracks) at regions with increased signal for H3K27Ac histone mark (upper two tracks) on new PU.1 peaks (bottom two tracks)
detected at the Evi2a locus for PU.1+ (red) and PU.1− (blue) conditions. (b) Global CEBPA-binding site comparison between PU.1− and PU.1+
conditions. (c) Read count comparison between PU.1− and PU.1+ conditions, plotted as log2 of normalised read counts (per million reads) at
CEBPA-bound regions, is shown. Line corresponding to direct correlation (no change) is depicted. (d) Three different groups of CEBPA-bound
regions were deﬁned. Firstly, read count comparison for regions bound by CEBPA in PU.1− and PU.1+ conditions were plotted (log2
normalised read count). Regions with no change in CEBPA binding deﬁned Group III (25107 regions shown in green). Then, H3K27Ac read
count comparison in PU.1− and PU.1+ conditions for regions with ⩾ fourfold change in CEBPA comparison (shown in yellow) was plotted.
Regions with no change in H3K27Ac enrichment deﬁned Group II (21 regions shown in blue). Regions with ⩾ 50 counts integrated Group I
(405 regions, shown in red). Line corresponding to direct correlation (no change) is shown in both plots. Threshold corresponding to 50
counts is shown in H3K27Ac read count comparison plot by dashed line. Regions were then associated to genes and distribution of promoter,
intragenic and intergenic localisation of the regions for each of the three groups is shown. (e) Global binding site comparison between CEBPA
Group I peaks and PU.1 Group I peaks. (f) Global binding site comparison between CEBPA Group I peaks and PU.1 Group III peaks.
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DISCUSSION
Relevance of Pu.1 mutations
Mutations in the Pu.1 DNA-binding domain are common in
radiation-induced murine leukaemia,19 although not in human
AML.47 Within the DNA-binding domain, R235 is highly conserved
across species, and structural studies have shown that it has a
crucial role in DNA binding at the GGAA core of the Ets motif,
leading to the prediction that DNA binding would be impossible
in its mutated state.3 Unexpectedly, our ChIP data clearly
demonstrate the DNA-binding capacity of this mutant PU.1
protein. However, a prominent overlap with PU.1-binding proﬁles
in macrophages was only observed following the expression of
wild-type PU.1, suggesting that it is the limited binding ability of
mutant PU.1 rather than complete absence which causes
differentiation block. Consistent with this notion, the expression
of wild-type PU.1 increased histone acetylation at a subset of
newly bound regions, and the concomitant upregulation of
neighbouring genes identiﬁed a gene set associated with
monocyte differentiation.
Effect of PU.1 induction on CEBPA distribution
It is well recognised that many myeloid gene regulatory elements
are simultaneously activated by PU.1 and CEBPA.44,45 Although
CEBPA has been reported to inhibit PU.1 function by displacing
the co-activator c-Jun from binding to the B3/B4 region of the
DNA-binding domain,48 positive interactions between PU.1 and
CEBPA are exempliﬁed by CEBPA-mediated activation of Pu.1
expression by binding to the PU.1 promoter49 and Upstream
Regulatory Element enhancer sites,50,51 and PU.1 regulation of
CEBPA expression by binding at the CEBPA +37 enhancer region.52
Given this complex interplay, the ratio of PU.1 to CEBPA has been
argued to determine whether cell fate is predominantly monocytic
or granulocytic9,21 with modelling predicting a bistable differ-
entiation potential between the two lineages when both TFs are
highly expressed.53
In our system, CEBPA binding was widespread both before and
after wild-type PU.1 induction, but we were able to identify a
group likely to represent new and functionally signiﬁcant events.
As with PU.1, the relative depletion of these peaks in non-
enhancer regions suggests cell-type-speciﬁc functionality. The
ﬁnding that 87.7% of these were also bound by PU.1 Group I
peaks indicates that this discrete subgroup of CEBPA-binding sites
are ‘bookmarked’ by the presence of PU.1 to facilitate subsequent
binding.
It therefore appears that a proportion of normal CEBPA-binding
events are impaired by the absence of PU.1 in the leukaemic
phase, which may contribute to the differentiation block seen in
PU.1-dysregulated leukaemias. Our ﬁndings are consistent with a
non-leukaemic PuER model of Pu.1-/- cells, where a relatively small
group of CEBPB peaks were observed after PU.1 induction with
strong enrichment for PU.1 motifs, and were co-bound by PU.1 in
over 75% of cases.36 CEBPA co-localisation to existing PU.1 peaks
was also noted in a recent study of RUNX1-ETO knockdown in a
t(8;21) AML cell line.54
‘Functional’ PU.1 binding induces monocytic/macrophage
differentiation to overcome the leukaemia phenotype
PuER induction caused both quantitative and qualitative differ-
ences in binding between wild-ype and mutant PU.1, and induced
PU.1-binding sites with a concomitant increase in histone H3K27
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Figure 6. Increased Pu.1 binding and increased H3K27Ac enrichment deﬁne a set of target genes that can be used to classify primary AML
samples. (a) Unsupervised hierarchical clustering of gene expression from a large well-annotated AML dataset40 on basis of expression of 81 of
96 PU.1 target genes present in dataset (deﬁned in Figure 4). Colourings for FAB subtype and karyotype classiﬁcations are shown and deﬁned
clusters are indicated. Karyotype proportions (b) and PU.1 expression levels (c) in each of the three clusters are shown.
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acetylation were primarily localised to enhancers. Cell-type-
speciﬁc binding of PU.1 in non-leukaemic cells had previously
been reported to largely be enhancer-speciﬁc,36 and associated
with elevated H3K27 acetylation.55 These observations are there-
fore consistent with the notion that introducing wild-type PU.1
into this leukaemic model activates a transcriptional programme
related to normal cell maturation, overcoming the differentiation
block. Our ﬁndings not only provide a clearer understanding of
the mechanism for the role of PU.1 suppression in AML, but also
identify activation of PU.1 as a potential therapeutic target for
differentiation therapy in human AML.
Although PU.1 mutations are uncommon in human AML,25–27,47,56
upstream mechanisms causing reduced PU.1 expression and
function are well described for the fusion genes RUNX1-ETO11 and
PML-RARA,28,57 as well as by FLT3-ITD mutations.58,59 Analysis of
primary AML samples using the set of 96 PU.1 target genes,
clustered the majority of RUNX1-ETO and PML-RARA samples
together in a group characterised by low PU.1 expression. The
presence of other AML cases in this cluster suggests that other as
yet unidentiﬁed pathways may converge on PU.1 under-expression,
giving rise to a common molecular defect.
Although genome reprogramming technologies are already
showing potential in manipulating TF expression to alter
phenotype,60 it is difﬁcult to see at present how genetic targeting
will achieve the efﬁciency required to target all leukaemic cells
within a patient for effective differentiation. As ATRA has proved in
PML-RARA-driven AML,61 pharmacological interventions on the
other hand represent a potent method of overcoming differentia-
tion block and treating the leukaemia. Interestingly, PU.1 induction
has recently been demonstrated by intravenous cytokine
activation,62 and it may be that a small molecule-based therapeutic
to upregulate PU.1 and alter downstream target expression will have
clinical potential to treat PU.1-dysregulated AML.
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